2025
Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney
Takeda K, Tang H, Kumar D, Adeniran A, Cai G. Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney. American Journal Of Clinical Pathology 2025, 164: 192-199. PMID: 40418705, DOI: 10.1093/ajcp/aqaf023.Peer-Reviewed Original ResearchLymphoproliferative disordersRenal complicationsRenal involvementRenal massesCases of non-Hodgkin's lymphomaDiffuse large B-cell lymphomaCharacteristics of lymphoproliferative disordersMature B-cell neoplasmsLarge B-cell lymphomaHistological characteristics of patientsHistory of lymphomaLow-grade lymphomaNon-Hodgkin's lymphomaB-cell lymphomaB-cell neoplasmsInstitutional pathology databasePresentation of lymphomaCharacteristics of patientsR-CHOPAggressive lymphomaChemotherapy regimensLymphoma subtypesPathology databaseClinical presentationRenal biopsy
2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.Peer-Reviewed Original ResearchConceptsReduced intensity conditioning regimenIntensity conditioning regimenExtracorporeal photopheresisConditioning regimenChronic extensive GVHDTotal body irradiationChronic graftECOG-ACRINExtensive GVHDGVHD prophylaxisHost diseaseMycophenolate mofetilCell infusionMulticenter trialTolerogenic stateAggressive lymphomaBody irradiationMedian timeMyelodysplastic syndromeGrade 3Day 100PatientsCellular therapyConsecutive daysAdequate engraftment
2019
DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma
Wang M, Kibbi N, Ring N, Siddon A, Foss F, Totonchy M. DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. BMJ Case Reports 2019, 12: e230641. PMID: 31570354, PMCID: PMC6768350, DOI: 10.1136/bcr-2019-230641.Peer-Reviewed Original ResearchConceptsAnaplastic large cell lymphomaPrimary systemic anaplastic large cell lymphomaSystemic anaplastic large cell lymphomaLarge cell lymphomaPoor prognosisSubcutaneous nodulesCell lymphomaGenetic testingALK-negative anaplastic large cell lymphomaBrentuximab vedotin monotherapySetting of HIVHIV-negative patientsCases of AIDSAnaplastic lymphoma kinaseHIV/AIDSComplete remissionDiffuse lymphadenopathyDisease courseFavorable prognosisLymph nodesAggressive lymphomaLymphoproliferative disordersLymphoma kinaseLymphomaAIDS
2010
Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma
Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2010, 10: e43-e46. PMID: 21856550, DOI: 10.3816/clml.2010.n.074.Peer-Reviewed Original ResearchConceptsTumor lysis syndromePlasmablastic lymphomaLysis syndromeHIV-negative plasmablastic lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaBortezomib-based treatmentHIV-negative patientsDramatic clinical responseB-cell lymphomaWorld Health OrganizationClinical responseImmunocompetent patientsAggressive lymphomaRare lymphomaMultiple myelomaOptimal treatmentLymphomaPatientsHealth OrganizationSyndromeStandard recommendationsTreatmentMyelomaSubtypes
1996
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusMTX withdrawalLymphoproliferative disordersComplete remissionPolymerase chain reactionRheumatic diseasesPartial responseAbsence of EBVNegative Epstein-Barr virusEBV RNA transcriptsSpontaneous complete remissionLow-grade lymphomaCNS involvementExtranodal diseaseImmunosuppressive therapyMethotrexate therapyMTX therapyInitial managementAggressive lymphomaClinicopathologic featuresHodgkin's diseasePathologic findingsRheumatoid arthritisSitu hybridization studiesSpontaneous regression
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1991
Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R, Young R. Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma. Journal Of Clinical Oncology 1991, 9: 710-710. DOI: 10.1200/jco.1991.9.4.710.Peer-Reviewed Original ResearchSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaComplete response rateCo-trimoxazole prophylaxisDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1989
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.Peer-Reviewed Original ResearchConceptsInvolved field radiation therapyRadiation therapyComplete remissionAggressive lymphomaCoronary artery bypass surgeryInvolved-field radiation therapyEarly hematogenous disseminationLocalized aggressive lymphomaTreatment-related deathsClinical stage IHigh-dose methotrexateArtery bypass surgeryCombination chemotherapy programsCycles of treatmentMedian followAggressive histologyBypass surgeryLeucovorin rescueChemotherapy programCombination chemotherapyHospital admissionLocal therapyHematogenous disseminationEffective treatmentLymphoma histology
1988
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.Peer-Reviewed Original ResearchConceptsResidual abdominal massesClinical complete remissionAbdominal massAggressive lymphomaNational Cancer InstituteStable residual massComplete remissionCombination chemotherapyPathologic evaluationFull-dose combination chemotherapyResidual massSubsequent tumor necrosisViable lymphoma cellsEvidence of diseaseMonths of chemotherapyInitial tumor sizeRestaging laparotomyBulky diseaseNegative laparotomyDisseminated diseaseIntraabdominal diseaseMost patientsSurgical explorationResidual tumorResidual diseaseThe role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1985
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Geffen D, Fisher R, Longo D, Young R, DeVita V. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. Journal Of Clinical Oncology 1985, 3: 646-53. PMID: 3998781, DOI: 10.1200/jco.1985.3.5.646.Peer-Reviewed Original ResearchConceptsNormal renal functionSerum creatinine levelsRenal involvementDiffuse aggressive lymphomasRenal functionCombination chemotherapyCreatinine levelsAggressive lymphomaElevated serum creatinine levelInitial local controlRecurrent renal diseaseEvidence of diseaseSite of recurrenceResults of treatmentComplete remissionDisseminated diseaseRenal diseaseSystemic diseaseHodgkin's lymphomaComplete resolutionRadiographic criteriaPatientsLocal controlLymphomaChemotherapyTreatment of diffuse large cell non-Hodgkin’s lymphomas
Fisher R, Devita V, Longo D, Ihde D, Young R. Treatment of diffuse large cell non-Hodgkin’s lymphomas. Developments In Oncology 1985, 465-469. DOI: 10.1007/978-1-4613-2607-6_49.Peer-Reviewed Original ResearchLong-term disease-free survivalDisease-free survivalAdvanced stageAdvanced diffuse histiocytic lymphomaDiffuse mixed lymphomaDiffuse histiocytic lymphomaDiffuse large cellDiffuse aggressive lymphomasLarge cell lymphomaComplete remissionComplete respondersCombination chemotherapyMixed lymphomaAggressive lymphomaHodgkin's lymphomaHistiocytic lymphomaTherapeutic resultsCell lymphomaBurkitt's lymphomaLymphomaFatal diseaseTreatment programPatientsSurvivalLarge cells
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
FISHER R, DeVITA V, HUBBARD S, LONGO D, WESLEY R, CHABNER B, YOUNG R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply